Purple Biotec-L stock analysis
Want to see IL:PPBT.L full AI Analyst Report?
Purple Biotec-L (PPBT.L) Stock Price & Analysis
PPBT.L Stock Chart & Stats
- Day’s Range
- ILA 0.00 - ILA 0.00
- 52-Week Range
- ILA 1.00 - ILA 1.60
- Previous Close
- ILA 1.00
- Volume
- N/A
- Average Volume (3M)
- 11.67K
- Market Cap
- ILS 32.42M
- Enterprise Value
- ILS 3.76M
- Total Cash (Recent Filing)
- ILS 6.11M
- Total Debt (Recent Filing)
- ILS 134.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.24
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Oct 30, 2012
- Dividend Yield
- N/A
PPBT.L FAQ
What was Purple Biotec-L’s price range in the past 12 months?
What is Purple Biotec-L’s market cap?
When is Purple Biotec-L’s upcoming earnings report date?
Is Purple Biotec-L overvalued?
Does Purple Biotec-L pay dividends?
What is Purple Biotec-L’s EPS estimate?
How many shares outstanding does Purple Biotec-L have?
Which hedge fund is a major shareholder of Purple Biotec-L?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Purple Biotec-L
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Isaac Israel
- Employees
- 10
- Website
- purple-biotech.com
- Address
- 4 Oppenheimer Street, Rehovot, TA, 7670104, IL
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 13 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 2 | 0 | 10 |

